A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).

Authors

null

David F. McDermott

Beth Israel Deaconess Medical Center, Boston, MA

David F. McDermott , Michael B. Atkins , Robert J. Motzer , Brian I. Rini , Bernard J. Escudier , Lawrence Fong , Richard Wayne Joseph , Sumanta K. Pal , Mario Sznol , John D. Hainsworth , Walter Michael Stadler , Thomas E. Hutson , Alain Ravaud , Sergio Bracarda , Cristina Suarez , Toni K. Choueiri , YounJeong Choi , Mahrukh A. Huseni , Gregg Daniel Fine , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Track

Renal Cell Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT01984242

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 431)

DOI

10.1200/JCO.2017.35.6_suppl.431

Abstract #

431

Poster Bd #

B14

Abstract Disclosures